(OAKVILLE, Ontario) July 13, 2022 – Very pleased and proud to announce that our ForYOU Patient Support Program is up and actively supporting Canadian patients. Officially launched and enrolling patients in need as of July 4, with the first dispense of XPOVIO in...
(OAKVILLE, Ontario) le 7 juin 2022 – FORUS Therapeutics Inc. (« FORUS »), a le plaisir d’annoncer que le 31 mai 2022, Santé Canada a autorisé la vente de XPOVIO® (selinexor) en association avec le bortézomib et la dexaméthasone pour le traitement des patients...
(Saint-lgnace-de-Stanbridge, Quebec) May 28th, 2022 – FORUS was a proud sponsor and participant in the Défi Cyclo-Myélome. This is the 10th year of this important event which aims to increase awareness about multiple myeloma and raise funds for the Myeloma Canada...
(TORONTO, Ontario) May 2-3, 2022 – FORUS Therapeutics Inc, a Canadian Life Sciences company specialized in developing and commercializing unique and differentiated oncology focused therapies is proud to be participating and presenting at the 2022 Bloom Burton &...
(OAKVILLE, Ontario) February 22, 2022 – FORUS Therapeutics, a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer, today announced it has secured $2.5M CAD in growth capital...
FORUS Therapeutics a le plaisir d’annoncer la nomination de Marie-Josèphe Champagne au poste de liaison médicale scientifiques principale pour le Québec et l’Atlantique. Marie-Josèphe a plus de 18 ans d’expérience dans l’industrie pharmaceutique dans des rôles...
Recent Comments